LumiThera, Inc. to Debut Valeda Light Delivery System at the 18th Congress of the European Society of Retina Specialists (EURETINA) in Vienna, Austria
SEATTLE, /PRNewswire/ --LumiThera® Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and diseases, announced that it will participate in the combined exhibition of the 18th EURETINA Annual Meeting and the 36th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), held in Vienna, Austria from the 20th to the 26th of September 2018.
EURETINA actively promotes new diagnostic developments, advances in vitreoretinal surgery, the development and application of new drugs, and changes in the treatment of macular degeneration.
LumiThera will debut the Valeda™ Light Delivery System for the treatment of dry AMD in the exhibition hall and will host a symposium on PBM technology entitled, "Photobiomodulation: An Innovative, Mitochondria-targeted Therapy for Dry AMD and Other Ocular Diseases" on September 20th.
"Valeda is our first commercial product and we are excited to launch at EURETINA," stated Clark E. Tedford, President and CEO of LumiThera. "We are also delighted to be sponsoring a symposium on PBM with four experts in the ophthalmology field. We believe the symposium will provide researchers and physicians the background, science, and patient benefits of PBM therapy and the latest on the development of the Valeda Light Delivery System for the treatment for dry AMD."
"I have been conducting research in PBM in ocular indications for many years and LumiThera's efforts to bring this therapy to the physicians and patients is incredible," commented Janis Eells, Ph.D., Professor, University of Wisconsin-Milwaukee. "I am happy to moderate the PBM symposium and look forward to teaching others about the potential of PBM therapy in ocular disease."
LumiThera recently presented top line data from the LIGHTSITE I study at the ARVO conference in May 2018 and has a multi-center trial in Europe planned to begin in the near term to further support clinical and anatomical benefits with the Valeda Light Delivery System. The therapy consists of a series of light-based treatments to the retinal cells, resulting in improved energy production and addressing inflammation, ischemia and metabolic dysfunction that contribute to disease.
About LumiThera, Inc.
The Valeda Light Delivery System has been granted authorization to use the CE Mark by an EU Notified Body as required for commercial use in the European Union only. Valeda is not approved for use by the Food & Drug Administration (FDA) in the USA.
2018 LumiThera, Inc., All rights reserved.
View original content:http://www.prnewswire.com/news-releases/lumithera-inc-to-debut-valeda-light-delivery-system-at-the-18th-congress-of-the-european-society-of-retina-specialists-euretina-in-vienna-austria-300712712.html
SOURCE LumiThera Inc.